Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod for Residual Lentigo Maligna After Excision
NCT01088737Phase 3Unknown
- Sponsor
- Medical University of Graz
- Start
- Jan 2011
- Primary completion
- Dec 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of imiquimod in lentigo maligna (LM), lentigo maligna melanoma (LMM), sponsored by Medical University of Graz. Status: unknown.
02
Drugs
imiquimod
03
Conditions
lentigo maligna (LM)lentigo maligna melanoma (LMM)
Beyond the preview
Go deeper on NCT01088737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01088737.